ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

NIH Limits Increases In Competing Renewals To Biomedical Deflator

August 30, 1991

Pediatric CCP Controversy Splits Group Leaders; National Consortium Forms; NCAB to Watch Closely

January 14, 1983

Lung, Head & Neck Treatment Advances Reported At ASCO Annual Meeting

May 27, 1977

Rauscher Tabs Oak Ridge Immunologists To Head Basic Research At Frederick

August 30, 1974

In Brief: Baltimore Names ACS Research Professor; Currie, Sachdeva Lead Education Association

December 9, 1994

ODAC’s Dilemma: Proposed Indication Created By Reliance On PSA Screening and Hormonal Treatment

September 23, 2011